Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase

American Journal of Pathology

Volumn 153, Issue 6, 1998, Pages 1947-1956

  Mitsiades, Nicholas ^a,b   Poulaki, Vassiliki ^a   Kotoula, Vassiliki ^a   Leone, Alvaro ^a   Tsokos, Maria ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; PHENANTHROLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELLULAR DISTRIBUTION; ENZYME ACTIVITY; EWING SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LEUKEMIA CELL LINE; LIGAND BINDING; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 0031740779     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65708-2     Document Type: Article

References (55)

1. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178
2. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995, 14:1129-1135
3. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nat Med 1996, 2:317-322
4. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995, 182:1777-1783
5. Mariani SM, Matiba B, Baumler C, Krammer PH: Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995, 25:2303-2307
6. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC: Human monocytic cells contain high levels of intracellular Fas ligand. Rapid release following cellular activation. J Immunology 1997, 159:1594-1598
7. Martinez-Lorenzo MJ, Alava MA, Anel A, Pineiro A, Naval J: Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 1996, 89:511-517
8. Oehm A, Berhmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, Ponstingl H, Krammer PH: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the TNF/NGF receptor superfamily. J Biol Chem 1992, 267:10709-10715
9. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ Force WR, Lynch DH, Ware CF, Green DR: Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995, 373: 441-444
10. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995, 373: 444-448
11. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hentgartner H, Golstein P: Fas and perforin pathways as major mechanisms of T-cell mediated cytotoxicity. Science 1994, 265:528-530
12. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perforin, and Fas lytic pathways. Nature 1994, 370:650-652
13. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani S, Weller M, Aebischer P, Krammer P, Fontana A: Local Fas/Apo-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995, 25:2253-2258
14. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996, 184:1075-1082
15. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996, 274:1363-1366
16. Horowitz ME, DeLaney TF, Malawar MM, Tsokos MG: Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In Principles and Practice of Pediatric Oncology. PA Pizzo and DG Poplack, editors. Philadelphia, JB Lippincott, 1993, pp 795-821
17. Cavazzana AO, Navarro S, Noguera R, Reynolds PC, Triche TJ: Olfactory neuroblastoma is not a neuroblastoma but is related to primitive neuroectodermal tumor (PNET). Prog Clin Biol Res 1988, 271:463-473
18. Sorensen PHB, Liu XF, Delattre O, Rowland JM, Biggs CA, Thomas G, Triche TJ: Reverse transcriptase PCR amplification of EWS/FLI-1 fusion transcripts as a diagnostic test for peripheral primitive neuroectodermal tumors of childhood. Diagn Mol Pathol 1993, 2:147-157
19. Sorensen PHB, Wu JK., Berean KW, Lim JF, Donn W, Frierson HF, Reynolds CP, L-pez-Terrada D, Triche TJ: Olfactory neuroblastoma is a peripheral primitive neuroectodermal tumor related to Ewing's sarcoma. Proc Natl Acad Sci USA 1996, 93:1038-1043
20. Whang-Peng J, Triche TJ, Miser J, Kao-Shan S, Tsai S, Israel M: Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet Cytogenet 1986, 21:185-208
21. Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tseleni-Balafouta S, Koutras DA, Tsokos M: Fas/Fas ligand up-regulation, and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis: J Clin Endocrinol Metab 1998, 83:2199-2203
22. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H: Expression of fas ligand in liver metastases of human colonie adenocarcinomas. Proc Natl Acad Sci USA 1997, 94:6420-6425
23. Sata M, Walsh K: TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation: Nat Med 1998, 4:415-420
24. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A rale for CD95 ligand in preventing graft rejection. Nature 1995, 377: 630-632
25. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand induced apoptosis as a mechanism of immune privilege. Science 1995, 270:1189-1192
26. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, Muller C. Tschopp J: Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996, 133:335-343
27. Runic R, Lockwood CJ, Ma Y, Dipasquale B, Guller S: Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J Clin Endocrinol Metab 1996, 81:3119-3122
28. Sato K, Kimura F, Nakamura Y, Murakami H, Yoshida M, Tanaka M, Nagata S, Kamatani Y, Wakimoto N, Nagata N, Motoyoshi K: An aggressive lymphoma accompanied by high levels of soluble FasL. Br J Haematol 1996, 94:379-382
29. Perzova R, Loughran T: Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br J Haematol 1997, 197:123-126
30. Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, Geley S, Kofler R, Greil R: Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997, 90:12-20
31. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA: Human lung carcinomas express Fas ligand. Cancer Res 1997, 57:1007-1012
32. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med 1996, 12:1361-1366
33. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnunger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY: Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997, 99:1173-1178
34. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H: Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 1997, 7:863-869
35. Spremuli EN, Dexter DL: Human tumor cell heterogeneity and metastasis. J Clin Oncol 1983, 1:496-509
36. Fidler IJ: Origin and biology of cancer metastasis. Cytometry 1989, 10:673-680
37. Weiss L: Metastatic inefficiency. Adv Cancer Res 1990, 54:159-211
38. Talmadge JE, Wolman SR, Fidler IJ: Evidence for the clonal origin of spontaneous metastases. Science 1982, 217:361-363
39. Chambers AF, Wilson S: Use of NeoR B16F1 murine melanoma cells to assess clonality of experimental metastases in the immune-deficient chick embryo. Clin Exp Metastasis 1988, 6:171-182
40. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J: Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998, 187:1205-1213
41. Tanaka M, Itai T, Adachi M, Nagata S: Downregulation of Fas ligand by shedding. Nat Med 1998, 4:31-36
42. Tsokos M, Vassilopoulos D, Szentendrei T, Quezado M, Karamens A, Tsokos G: Fas-mediated apoptosis in peripheral primitive neuroectodermal tumors (PNET) Ewing's sarcoma (ES). FASEB J 1996, 10: A 1009 (Abstr)
43. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Navee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woodley K: Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994, 370:555-557
44. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K: Matrix metalloproteinases and processing of pro-TNF-α. J Leukoc Biol 1995, 57:774-777
45. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassle D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Panel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Warner J, Willard D, Becherer JD: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997, 385:733-736
46. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997, 385:729-733
47. McGeehan GM, Becherer JD, Bast Jr RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwansky KM, Schoenen F, Sekut L, Truesdale A, Verghese M, Warner J, Ways JP: Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994, 370:558-561
48. Middelhoven PJ, Ager A, Roos D, Verhoeven AJ: Involvement of a metalloprotease in the shedding of human neutrophil Fc gammaRIIIB. FEBS Lett 1997, 414:14-18
49. Ancuta P, Fahmi H, Pons JF, Le Blay K, Chaby R: Involvement of the membrane form of tumour necrosis factor-α in lipopolysaccharide-induced priming of mouse peritoneal macrophages for enhanced nitric oxide response to lipopolysaccharide. Immunology 1997, 92: 259-266
50. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89:1260-1270
51. Rasmussen HS, McCann PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997, 75:69-75
52. Bramhall SR: The matrix metalloproteinases and their inhibitors in pancreatic cancer: from molecular science to a clinical application, Int J Pancreatol 1997, 21:1-12
53. Denis LJ, Verweij J: Matrix metalloproteinase inhibitors: present achievements and future projects. Invest New Drugs 1997, 15:175-185
54. Wojtowicz-Praga, SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 1997, 15:61-75
55. Stettler-Stevenson WG: Dynamics of matrix turnover during pathologic remodelling of the extracellular matrix. Am J Pathol 1996, 148: 1345-1350